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Abstract 
Background: Patients infected with the human immunodeficiency virus (HIV) are more prone to systemic inflam-
mation and pathological clotting, and many may develop deep vein thrombosis (DVT) as a result of this dysregulated 
inflammatory profile. Coagulation tests are not routinely performed unless there is a specific reason.
Methods: We recruited ten healthy control subjects, 35 HIV negative patients with deep vein thrombosis (HIV 
negative-DVT), and 13 HIV patients with DVT (HIV positive-DVT) on the primary antiretroviral therapy (ARV) regimen-
emtricitabine, tenofovir and efavirenz. Serum inflammatory markers, haematological results, viscoelastic properties 
using thromboelastography (TEG) and scanning electron microscopy (SEM) of whole blood (WB) were used to com-
pare the groups.
Results: The DVT patients (HIV positive and HIV negative) had raised inflammatory markers. The HIV positive-DVT 
group had anaemia in keeping with anaemia of chronic disorders. DVT patients had a hypercoagulable profile on the 
TEG but no significant difference between HIV negative-DVT and HIV positive-DVT groups. The TEG analysis compared 
well and supported our ultrastructural results. Scanning electron microscopy of DVT patient’s red blood cells (RBCs) 
and platelets demonstrated inflammatory changes including abnormal cell shapes, irregular membranes and micro-
particle formation. All the ultrastructural changes were more prominent in the HIV positive-DVT patients.
Conclusions: Although there were trends that HIV-positive patients were more hypercoagulable on functional tests 
(viscoelastic profile) compared to HIV-negative patients, there were no significant differences between the 2 groups. 
The sample size was, however, small in number. Morphologically there were inflammatory changes in patients with 
DVT. These ultrastructural changes, specifically with regard to platelets, appear more pronounced in HIV-positive 
patients which may contribute to increased risk for hypercoagulability and deep vein thrombosis.
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Clinical implications
• HIV-positive patients do have a hypercoagulable pro-
file compared to HIV-negative patients.
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• Ultrastructural analysis, using the scanning electron 
microscope, allows a more detailed coagulation pro-
file, especially in HIV-positive patients.
Background
The prevalence of HIV and Acquired Immune Deficiency 
Syndrome (AIDS) is a world-wide pandemic. The Joint 
United Nations Programme on HIV/AIDS (UNAIDS) 
estimates that 1 million AIDS-related deaths occurred 
during 2016 [1] and 1.7 million (1.4 million–2.3 mil-
lion) people were newly infected with HIV by the end of 
2018 (http://www.unaid s.org/en/resou rces/fact-sheet ). 
Although treatment of the infection with antiretroviral 
regimes (ARVs) is essential to addressing the pandemic, 
the condition is characterized by a large plethora of addi-
tional conditions associated, and also co-existing with 
the HIV infection, including the presence of systemic 
inflammation. Systemic inflammation is associated with 
an increase in circulating pro-inflammatory biomarkers, 
and is closely associated with an amplified propensity to 
form pathological blood clots (which is associated with 
hypercoagulability or an over-activated coagulation sys-
tem) [2–8].
During HIV infection, various circulating inflamma-
tory biomarkers, including cytokines interleukin (IL)-1β, 
IL-2, IL-6, IL-8, IL-10, IL-12p70, tumor necrosis factor 
(TNF)-α and also other pro-inflammatory biomarkers are 
present [9]. An increase in these biomarkers are also pre-
sent in cardiovascular disease [10, 11] and it is therefore 
not surprizing that HIV positive individuals are known 
to have an increased presence of cardiovascular compli-
cations [12, 13], including an increased risk to develop 
atherosclerosis and venous thromboembolic disease 
[14] and also DVT [15–17]. The presence of DVT is also 
classified as a systemic inflammatory process [18], and 
associated with pathological clotting and upregulated cir-
culating inflammatory biomarkers [19].
The prevalence of developing a DVT in HIV posi-
tive individuals is increased two to ten times compared 
to the general population [20]. HIV positive individu-
als also have a 43% increase in age-adjusted odds ratio 
for pulmonary embolism, a common complication of 
DVT, compared to HIV negative individuals [16]. Mul-
tiple coagulation abnormalities have been reported in 
HIV positive patients such as decreased levels of protein 
C and S; and increased levels of von Willebrand factor 
[21–23]. However, the association of these abnormalities 
with DVT is not always consistent [21, 24]. Coagulation 
investigations are therefore not performed routinely in 
patients with HIV infection. Standard coagulation inves-
tigations are also not performed routinely as part of the 
management in patients with DVT, with the exception 
of a D-dimer which is used to assist with the diagnosis 
[25–27].
In the current paper, we therefore study the haemato-
logical profiles, including clotting and various inflamma-
tory markers, in the presence of DVT in HIV positive and 
HIV negative individuals and compare the results to that 
of healthy individuals. We compare inflammatory mark-
ers for iron (iron saturation, transferrin and serum ferri-
tin), fibrinogen, high-sensitive C-reactive protein (CRP), 
erythrocyte sedimentation rate (ESR) and haematology 
analyser results, together with viscoelastic properties of 
whole blood (WB) and platelet poor plasma (PPP). We 
also looked at ultrastructure of platelets and erythro-
cytes/red blood cells (RBCs) (using whole blood smears) 
with the SEM, as well as after thrombin was added to 
whole blood, to study clot structure.
Materials and methods
The aim was to compare the inflammatory and haemato-
logical profile of HIV patients with DVT to HIV negative 
patients with DVT. An analytical and descriptive pro-
spective case control study was used from 2 Pretoria aca-
demic hospitals, Kalafong Provincial Tertiary and Steve 
Biko Academic Hospital, both from urban South Africa. 
Ten healthy control subjects, 35 HIV negative patients 
with DVT (HIV negative-DVT), and 13 HIV patients 
with DVT (HIV positive-DVT) on the primary ARV 
regimen-emtricitabine, tenofovir and efavirenz—were 
recruited for the study. For each individual, five blood 
tubes of venous blood were drawn (this included ethyl-
enediamine tetraacetic acid, buffered tri-sodium citrate 
and serum separator tubes). The Research Ethic Com-
mittee, Faculty of Health Sciences, University of Pretoria, 
South Africa approved the study (Ethics reference num-
ber: 547/2015). Inclusion criteria for the healthy indi-
viduals were known HIV negative status and no medical 
history of any chronic diseases. Patients were included 
in the research groups if they had confirmed HIV status 
and confirmed symptomatic DVT on doppler ultrasound 
or comparative imaging, such as a venogram or comput-
erised tomography scan. In order to minimise oppor-
tunistic infections as a confounding factor, HIV positive 
patients were only included with a World Health Organi-
zation Clinical stage 1 and CD4+ cells greater than 170 
absolute number (per  mm3). Exclusion criteria for the 
healthy individuals and for DVT patients include smok-
ing, pregnancy‚ or the use of any inflammatory-, anti-
coagulant-, antiplatelet-, hormone replacement- or oral 
contraceptive- medication.
Inflammatory marker analysis
Serum iron (total iron in blood) levels were measured 
together with iron saturation, transferrin (iron binding 
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protein) and serum ferritin (iron storage form). Serum 
iron levels were measured by a modification of the 
automated AAII-25 colorimetric method. Fibrinogen 
(quantitative measurement of functional fibrinogen by 
automated coagulation analysers), CRP (measured by 
latex-enhanced nephelometry) and ESR (measured by an 
automated ESR analyser) levels were also assessed.
Haematology analysis
A haematology analyser (Advia 2120i, Siemens Health-
care) was used to do full blood counts, and the analysis 
included white cell count (and its differential count), RBC 
count, haemoglobin level, haematocrit, mean corpus-
cular volume (MCV), mean corpuscular haemoglobin 
(MCH), the mean corpuscular haemoglobin concentra-
tion (MCHC), as well as platelet count and mean platelet 
volume (MPV).
Viscoelastic properties of whole blood and platelet poor 
plasma using thromboelastography
Citrated WB, as well as PPP were used. Whole blood, 
collected in a citrate tube, was centrifuged to obtain PPP 
(15  min at 3000g). Whole blood was used to assess the 
full coagulation process, while PPP was used to assess 
coagulation without the influence of platelets and RBCs 
on the viscoelastic properties of the clot. Calcium chlo-
ride was added to either WB or PPP and 7 different 
parameters measured, which included: reaction time 
(R-time), kinetic time (K-time), alpha angle, maximum 
amplitude (MA), maximum rate of thrombus generation 
(MRTG), time to maximum rate of thrombus generation 
(TMRTG) and total thrombus generation (TTG).
Ultrastructure of platelets and red blood cells (RBCs)
The ultrastructure of platelets and RBCs were studied 
after preparing whole blood smears for scanning electron 
microscopy (SEM). 10  µl of WB was placed directly on 
a glass microscope slide, followed by fixing in 2.5% glu-
taraldehyde, dehydration (as per usual SEM preparation) 
[28] and mounting. Micrographs were taken with Zeiss 
Crossbeam 540 Field Emission Gun Scanning Electron 
Microscopy.
Statistical analysis
Statistical analyses were performed on GraphPad Prism 
5. All data were subjected to one-way ANOVA analy-
sis. A post-test to compare groups was performed using 
Tukey’s multiple comparison test. Values of significance 
stated at P < 0.05.
Results
Table 1 demonstrates the demographics of the study.
Inflammatory marker and haematological parameter 
analysis
Inflammatory marker analyses are shown in Table 2 and 
haematology analysis are shown in Table 3. Markers with 
no available results were excluded. The HIV negative-
DVT group appeared to have anaemia when compared to 
the control group, but when adjusted for gender the HIV 
negative-DVT group still had haemoglobin mean values 
within the normal reference ranges for male and females, 
respectively‚ and only the females had decreased serum 
iron, transferrin, and ferritin levels. The HIV positive-
DVT group had anaemia and‚ when adjusted for gender‚ 
demonstrated low haemoglobin levels for both males and 
females (furthermore the females also had decreased red 
cell count, haematocrit, mean cell volume and mean cell 
haemoglobin concentration), as well as decreased lev-
els of serum iron and transferrin in both genders. The 
changes in serum iron, transferrin and ferritin in the HIV 
positive-DVT group reflects low systemic iron status, 
but the raised serum ferritin (although not statistically 
significant) may be due to the inflammatory status of the 
individuals. 
Inflammation is reflected, whether from the DVT or 
the HIV infection, by the raised CRP and ESR. Surpris-
ingly, the platelet count was not decreased in the HIV 
positive-DVT group. We expected this parameter, as well 
as the MPV to be markedly decreased, due to, e.g. HIV 
thrombocytopaenia, which is usually common amongst 
HIV patients, but in our sample this was not the case.
Thromboelastography
Table  4 shows a comparison of the WB and PPP TEG 
results between the various groups. The WB and PPP, in 
the HIV negative-DVT and HIV positive-DVT groups, 
Table 1 Demographics
N/A not applicable
Groups N Male Female Age-mean (range) CD4 count-mean (range)
Controls 10 6 4 30 (26–32) N/A
HIV negative-DVT 35 11 24 51(19–81) N/A
HIV positive-DVT 13 2 11 41 (24–69) 511 (178–1764)
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are suggestive of clot hypercoagulability and it is reflected 
by a rapid R-time, K-time, MRTG and TMRTG. However, 
with regard to the WB, only the R-time and TMRTG in 
the HIV-DVT group compared to the control group; and 
only the TMRTG in the HIV negative-DVT group com-
pared to the control group were statistically significant. 
The PPP only demonstrated a statistically significant dif-
ference with the K-time in both the DVT groups (HIV 
positive and HIV negative) compared to the control 
group. Interestingly, there were no significant differences 
in hypercoagulability between the HIV positive-DVT and 
the HIV negative-DVT groups.
Scanning electron microscopy
SEM micrographs of representative healthy RBCs and 
platelets are shown in Fig.  1, while Figs.  2 and 3 show 
SEM of RBCs and platelets in HIV negative-DVT and 
HIV positive-DVT patients.
Discussion
Both DVT groups (HIV negative and HIV positive 
groups) had parameters suggesting anaemia com-
pared to the control group (Table  3). However, the 
RBC count, Hb and Hct levels in the HIV negative-
DVT group, even though lower than the control group, 
are still within the normal reference ranges [29]. The 
Hb and Hct in the HIV positive-DVT group were sig-
nificantly lower than both the HIV negative-DVT and 
control groups; and lower than the normal reference 
ranges indicating an anaemia. Anaemia is commonly 
found in HIV positive patients but the cause of the 
anaemia is not always clear [30–35]. An inadequate 
erythropoietin feedback mechanism is suspected to be 
a major contributor in HIV-related anaemia [30]. A low 
reticulocyte count is commonly found with associated 
polychromasia (abnormally high number of immature 
RBCs), indicating a possible under-producing bone 
marrow [30, 36–38]. Other factors that contribute to 
HIV-associated anaemia, includes intestinal malab-
sorption, autoimmune haemolysis, bone marrow malig-
nancies, blood loss and opportunistic complications 
[30, 32, 38, 39]. Even with the decreased RBC count, 
Hb and Hct levels in the HIV negative-DVT group (as 
compared to the control group), there were no signifi-
cant differences with MCV, MCH as well as MCHC 
(Table 3). The changes in the HIV negative-DVT group 
Table 2 Analysis of inflammatory markers using one-way ANOVA with Tukey’s multiple comparison test
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may support an anaemia typically associated with 
inflammation, also known as anaemia of chronic disor-
ders [30, 40].
The RCDW is the coefficient of variation of RBC 
volume. The higher the value, the more anisocytosis 
(unequal RBC sizes) present. The RCDW of the HIV 
positive-DVT group was greater than the control and 
HIV negative-DVT groups (Table 3). A raised RCDW is 
commonly associated with a decrease in haemoglobin 
and MCV concentration; but with a raised CRP, fibrin-
ogen and white cell count [41]. This correlates with the 
haematological and inflammatory markers found in 
the HIV positive-DVT group (Tables  2, 3). RCDW is 
strongly associated with mortality. Patel and colleagues 
reported the all-cause mortality risk increases by 22% 
for every 1% increase in RCDW. Furthermore, the phys-
iological association between RCDW and mortality has 
been hypothesised to be related to the systemic fac-
tors involved in inflammatory conditions and oxidative 
stress which affects erythrocyte maturation and degra-
dation [41–43].
The ESR is the extent in which erythrocytes sediment 
in 1 h [44]. The ESR in both the HIV negative-DVT and 
HIV positive-DVT groups were raised compared to the 
control group (Table 2). In inflammatory conditions the 
ESR rises as the erythrocytes become sticky and adhere 
to each other which can be seen as rouleaux formation 
[45–47].
Fibrinogen, a high molecular weight plasma protein, 
is a crucial factor in the coagulation pathway (factor I). 
Increased fibrinogen levels are associated with thrombo-
embolic events. Fibrinogen also has a role in inflamma-
tion as it tends to adhere to the membrane receptors of 
cells involved with inflammation. Fibrinogen can adhere 
to the RBCs, which becomes “heavier” resulting in an 
increased ESR and blood viscosity [48–55]. The fibrino-
gen levels were greater (but not statistically significant) 
in the HIV negative-DVT and HIV positive-DVT groups 
compared to the control group (Table  2) which cor-
relates with the raised ESR levels seen in both groups. 
Increase fibrinogen concentration in the inflammatory 
response can explain the raised fibrinogen concentration 
Table 3 Analysis of haematological markers using one-way ANOVA with Tukey’s multiple comparison test
Haem. haematological, HIV human immunodeficiency virus, vs. versus, RCC red cell count, Hb haemoglobin, Hct haematocrit, MCV mean corpuscular volume, MCH 
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in the HIV positive-DVT group which contributed to the 
DVT. The concurrent use of ARV medication has not 
been shown to affect the fibrinogen concentration [56]. 
The HIV negative-DVT group with a raised fibrinogen 
concentration is either due to the DVT resulting in the 
inflammatory response (and the raised fibrinogen con-
centration) or the raised fibrinogen concentration con-
tributing to the DVT.
The WCC in the HIV positive-DVT group was sta-
tistically significantly raised compared to the control 
group (Table  2), although still within the normal refer-
ence range. Similar to patients with ischemic strokes, 
thromboembolism results in an inflammatory reaction 
with raised leukocyte count and CRP [57, 58]. CRP, like 
the leukocyte count, is an important indicator of inflam-
matory conditions [59]. HIV is usually associated with 
a decreased immune function. The elevated leukocyte 
count in these HIV positive-DVT patients may be due 
to the HIV infection itself or to opportunistic infections, 
regardless of whether the patient has a DVT or not. Also, 
with the ARV treatment HIV is suppressed and the lym-
phocytes, particularly the CD4 lymphocytes, increase in 
turnover [60–62]. The concentration of CRP is increased 
by proinflammatory cytokines, interleukin 1 and 6 [63]. 
The HIV negative-DVT group has an inflammatory 
response to the DVT which is reflected by the statistically 
significantly raised CRP levels compared to the control 
group (Table 2). The same argument can be made for the 
raised CRP in the HIV positive-DVT group, however the 
CRP concentration (as well as fibrinogen) is commonly 
raised in HIV positive patients compared to the general 
population even without a DVT [64–68]. The raised CRP 
in HIV positive-DVT patients (Table 2) indicates a sus-
tained acute phase response [66]. This was statistically 
Table 4 TEG results of WB and PPP using one-way ANOVA with Tukey’s multiple comparison test
TEG thromboelastography, HIV human immunodeficiency virus, vs. versus, R reaction, K kinetics, MA maximum amplitude, MRTG maximum rate of thrombus 
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significant in the HIV positive-DVT group compared to 
the control group. The CRP in the HIV positive-DVT 
group was almost double compared to the HIV negative-
DVT group. Increasing CRP concentrations has been 
reported with HIV disease progression, and this increase 
does not appear to be affected by ARV treatment [63]. 
Previously it was noted that increased levels of CRP and 
fibrinogen are independently highly predictive of 5  year 
mortality risk in HIV positive patients, especially where 
the CD4 count is low [69, 70].
Considering all the inflammatory markers (WCC, 
fibrinogen, CRP and ESR), each marker was statisti-
cally significantly raised in the HIV positive-DVT group 
compared to the control group, with the exception of 
fibrinogen (Table  2). In the HIV negative-DVT group 
compared to the control group, only CRP was statistically 
significantly raised. CRP may therefore be a more sensi-
tive acute phase marker to differentiate an inflammatory 
condition between DVT patients (HIV negative and HIV 
positive) compared to healthy subjects. Interestingly, no 
inflammatory marker was statistically significantly raised 
in the HIV positive-DVT group compared to the HIV 
negative-DVT group.
The transferrin, serum iron and iron saturation levels 
reflects the amount of iron in the body. Transferrin is 
a plasma protein that transports iron in the blood [62], 
whereas ferritin is an intracellular structure capable of 
storing iron atoms. The concentration of serum ferritin is 
related to the reticuloendothelial iron stores [71]. Serum 
ferritin and iron concentrations are also indicators for 
acute phase responses to inflammation [71], although 
serum ferritin appears to be a better marker of inflamma-
tion than iron status [72].
Iron deficiency may be a contributor to anaemia in 
the HIV positive-DVT group in keeping with a low 
MCH and MCHC, although this is not reflected with 
the MCV which was within the normal reference range 
(Table 3) [73, 74]. A low serum iron and transferrin level 
seen in the HIV positive-DVT group, but with a raised 
ferritin level (as compared to the control group), can be 
explained by an immunologically altered iron metabo-
lism where the body has adequate or increased iron 
stores but is unable to utilize those stores [32, 37, 60, 61, 
71, 75–77]. This functional iron deficiency can be consid-
ered a host defence mechanism by withholding iron from 
possible pathogens [78, 79]. However, as iron is required 
Fig. 1 Scanning electron microscopy micrographs of a comparison with representative healthy RBCs from other studies [8], b representative 
healthy platelets (see arrows) and RBCs from the current study, c, d after addition of thrombin to whole blood, where fibrin fibres are formed over 
the discoid RBCs with no cellular distortion (from the current study)
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for normal immune function, iron deficiency can also 
increase the risk of infection [79].
Although the inflammatory RBC changes have been 
documented in non-communicable diseases, there are 
only a few reports of communicable diseases, specifi-
cally HIV, and the effect on RBCs and the coagulation 
system [80–85]. Multiple abnormal RBC shape changes 
and membrane abnormalities were noted in the patients 
with DVT (HIV negative and HIV positive groups) (Fig. 1 
to 3). During inflammatory diseases, RBCs exposed to 
oxidative stress and inflammatory molecules undergoes 
biochemical membrane changes which can result in bio-
physical shape changes and eryptotic cells [28, 86–93]. 
Eryptosis is a co-ordinated suicidal death of the red blood 
cells, similar to apoptosis, that allows for the removal 
of defective, infected or potentially harmful cells before 
they undergo haemolysis [94–98]. The abnormal RBCs 
present with an abnormal expression of phosphatidyl-
serine, a cell membrane lipid, on the external membrane 
layer. RBCs that display phosphatidylserine also contrib-
ute to the hypercoagulation state and they provide a pro-
thrombotic surface for the formation of thrombin [40, 96, 
99–110]. Membrane vesicle formation and microparticle 
shedding (microscopic extracellular membranous struc-
tures) were also seen in both DVT groups. RBC-derived 
microvesicles or microparticles, is known to be associ-
ated with the expression of phosphatidylserine [111]. 
RBC-derived microparticles appear to enhance thrombin 
generation resulting in a hypercoagulable state, such as in 
post transfusion DVT, sickle cell disease and haemolytic 
anaemia [112, 113]. As the microparticle presence might 
also be associated with increased thrombin presence, the 
complement system can therefore also be activated and 
thereby enhance the systemic inflammatory response 
which is also a hypercoagulable state [114]. Micropar-
ticles are also thought to originate from CD4 lympho-
cytes [115]. As the HIV virus infects CD4 lymphocytes, 
HIV positive patients may be more prone to developing 
microparticles and therefore enhancing the hypercoagu-
lable state.
Whole blood with thrombin SEM analysis showed 
the incorporation of RBCs into the fibrin network. The 
incorporation of RBCs into the fibrin network stabilises 
and strengthens the clot by decreasing the permeability 
of fibrin and increasing the resistance to fibrinolysis [4, 
116, 117]. Healthy (discoid) RBCs in netted fibrin fibers 
Fig. 2 Representative scanning electron microscopy micrographs of RBCs from HIV negative-DVT patients. a Whole blood with thrombin, showing 
RBC entrapped in fibrin matter, b RBCs agglutinated to each other (no thrombin), c higher magnification showing agglutinated plasma proteins 
attached to the RBC membrane and d a hyperactivated platelet
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are shown Fig. 1c, d. However, in our HIV negative-DVT 
and HIV positive-DVT groups, the RBCs are trapped in a 
matted fibrin fiber network. During inflammation, fibrin 
fibres tend to increase in diameter and assume a matted 
rather than a netted appearance; while their viscoelastic-
ity may also be influenced by the RBC inclusion in the 
fibrin network [99]. Also, under conditions of low partial 
pressure of oxygen, acidosis and in response to mechani-
cal deformation, RBCs release ATP and ADP activating 
platelets and promoting aggregation and release of plate-
let granules [113]. This can happen as part of the HIV 
and DVT pathology. The (hyper) activation of platelets, 
together with an abnormal matted fibrin network, con-
tracts the clot containing the trapped pathological RBCs 
into a tight package (Fig. 3b, c). The result is the forma-
tion of polyhedrocytes, which is commonly found in 
DVT [118].
Platelet functioning depends on the quality and the 
quantity of the platelets [119]. Platelet count is a measure 
of the number of platelets in a volume of blood. Throm-
bocytopenia (low platelet count) is a common finding 
in HIV positive patients, whether it be due to increased 
destruction or decrease production of platelet cells [56]. 
However, in this study both the HIV negative-DVT and 
HIV positive-DVT groups had a non-statistically signifi-
cant increase in the platelet count (Table 3). It should be 
noted that platelet count is not always associated with 
an increased risk of DVT [120]. The mean platelet vol-
ume measures the average size of platelets in the blood 
and is a common platelet activation marker [120–127]. 
An elevated MPV is associated with low-grade inflam-
mation as well as thrombosis [128]. However, both HIV 
negative-DVT and HIV positive-DVT groups had a 
decrease in the mean platelet volume compared to the 
control group (Table 3). These results may be in keeping 
with a venous thrombosis where the thrombus is due to 
activation of the coagulation cascade instead of platelets 
[129]. It should also be kept in mind that platelets shape 
and volume do vary, resulting in changes in MPV, even 
in healthy persons [127]. Together with these results, 
the ultrastructure of platelets in the HIV positive-DVT 
group also have features different to that of the control 
group and the HIV negative-DVT group (Figs. 1b, d, 3d). 
The control group and the HIV negative-DVT group 
have (hyper) activated platelet aggregates with smooth 
intact membranes, pseudopodia formation, openings of 
the open canalicular channels and membrane blebbing 
interspersed among smooth intact membranes. These are 
Fig. 3 Representative scanning electron microscopy micrographs of RBCs and platelets from HIV positive-DVT patients. a RBC with pathological 
membrane; b, c whole blood with thrombin, showing RBCs trapped in dense matted fibrin deposits and d a hyperactivated platelet
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the typical morphological features of activated platelets 
seen in healthy individuals [130]. The HIV positive-DVT 
patients have activated platelet aggregates which are also 
seen to have the same features; but with the addition of 
shrivelled aggregates with irregular membranes, torn 
membrane surface and shedding of procoagulant vesi-
cles. These features are suggestive of apoptosis, cell death, 
as was seen in the red blood cells. Similar ultrastructural 
changes in HIV patients were documented by Pretorius 
et al. in 2008 [80]. These ultrastructural changes may be 
due to altered viral infected megakaryocyte morphology 
or due to direct infection and damage by the HIV virus. 
The HIV virus may gain entry into the platelets by under-
going phagocytosis or through the openings of the open 
canalicular system channels [80, 131, 132]. Regardless of 
the way of entry, platelets containing the HIV virus are 
activated. It is not clear if the platelets containing the 
virus facilitates viral replication and spreading; or assists 
in clearance of the virus [131]. With the latter, the ultra-
structural changes may be due to the immune response 
of the body resulting in antibody-induced destruction 
of the platelets [80]. Antiretroviral medication has been 
shown to have platelet related effects such as a decreased 
prevalence of HIV associated thrombocytopaenia but 
may have an increased bleeding risk [133]. This increased 
bleeding risk may be explained by the ultrastructural 
changes seen on the SEM. It is possible that the use of 
different ARV combinations may result in different mor-
phological changes observed, however to standardize 
the results, only patients on the primary regimen were 
recruited for this study.
Our TEG analysis compared well and supported our 
ultrastructural results (Table 4). The HIV negative-DVT 
group compared to the control group showed significant 
differences with regards to TMRTG, while the HIV posi-
tive-DVT group compared to the control group, showed 
significant differences with regards to R-time, and the 
TMRTG. According to Pretorius and colleagues not all 
the parameters need be abnormal to indicate pathologi-
cal coagulability and the degree of coagulability can be 
related to the number of parameters that are abnormal 
[5].
Both DVT groups (HIV negative and HIV positive), 
using whole blood, indicate a hypercoagulable profile that 
has a rapid initiation and amplification, resulting in the 
rapid formation of thrombin. The TEG parameters in the 
HIV positive-DVT group compared to the HIV negative-
DVT group indicate a hypercoagulable profile but there 
were no statistical significance in any of the parameters. 
Both the HIV negative-DVT and HIV positive-DVT 
groups have rapid R-times and K-times (Table  4)  and 
trapped RBCs between a matted (hypercoagulable) 
fibrin network were noted. Considering that pulmonary 
embolism can result in up to 10% mortality [134] and half 
of the patients with DVT may have non-symptomatic 
(silent) pulmonary embolism [135], the changes found on 
the TEG and SEM may provide for a risk of assessment 
of the DVT complicating to pulmonary embolism. [136].
Conclusion
Although there were trends that HIV-positive patients 
were more hypercoagulable on functional tests (viscoe-
lastic profile) compared to HIV-negative patients, there 
were no significant differences between the 2 groups. The 
sample size was, however, small in number. Morphologi-
cally there were inflammatory changes in patients with 
DVT. These ultrastructural changes, specifically with 
regard to platelets, appear more pronounced in HIV-pos-
itive patients which may contribute to an  increased risk 
for hypercoagulability and deep vein thrombosis.
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